Business Wire

GA-TSYS

Del
TSYS Releases Research on U.K. Consumer Payments

TSYS (NYSE: TSS) has today published its inaugural U.K. Consumer Payments research report. This report includes information on key consumer payment preferences and new insights on a range of popular industry topics.

TSYS conducted quantitative research via a survey of more than 500 U.K. consumers, covering diverse demographics, including gender, age and income. The respondents were older than 17, had at least one debit card and one credit card, and owned a mobile phone.

"TSYS is committed to providing its clients and the wider industry with greater insights into current and evolving payment trends in the U.K. and Europe at large," said John Goodale, group executive, product and market development, TSYS International. “Our goal is to help card issuers deliver highly relevant payment strategies and initiatives, and we believe this serves as a useful tool for the industry in forming views on future trends.”

Key findings from the research include the following:

  • What distinguishes segments in a meaningful way is two-pronged: consumer comfort and increased use of digital tools, and a willingness to share data in return for value.
  • Consumers are more comfortable and competent in the use of apps and settings to manage their digital lives, and the preference for self-serve tools is extending to banking relationships.
  • E-commerce has reached mass adoption, with 56 percent of respondents indicating they keep a credit card on file with a retailer to make online purchases.

The report is available online at: http://tsys.com/2015ukconsumerpaymentsstudy/ .

About TSYS

At TSYS® (NYSE: TSS), we believe payments should revolve around people, not the other way around. We call this belief People-Centered Payments® . By putting people at the center of every decision we make, TSYS supports financial institutions, businesses and governments in more than 80 countries. Through NetSpend® , A TSYS Company, we empower consumers with the convenience, security, and freedom to be self-banked. TSYS offers issuer services and merchant payment acceptance for credit, debit, prepaid, healthcare and business solutions.

TSYS’ headquarters are located in Columbus, Ga., U.S.A., with local offices spread across the Americas, EMEA and Asia-Pacific. TSYS is a member of The Civic 50 and was named one of the 2015 World's Most Ethical Companies by Ethisphere magazine. TSYS routinely posts all important information on its website. For more, visit us at www.tsys.com .

Contact:

TSYS Media Relations
Cyle Mims, +1.706.644.3110
cylemims@tsys.com
or
TSYS International
Victoria Winn, +44.1904.562.577
victoriawinn@tsys.com

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release

IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye